Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preparing for the new anticoagulants.

Bruce L Davidson1

  • 1Division of Pulmonary and Critical Care Medicine, Swedish Medical Center and University of Washington School of Medicine, Seattle, WA. brucedavidson@pobox.com

Journal of Thrombosis and Thrombolysis
|February 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized comparison of intramuscular high-dose versus oral maintenance vitamin D to prevent severe exacerbations in deficient/insufficient asthmatic children.

The journal of allergy and clinical immunology. Global·2025
Same author

Pulmonary embolism prophylaxis and treatment: What's right, what's wrong, and the future.

Chinese medical journal pulmonary and critical care medicine·2025
Same author

Missing Pertinent Information Regarding Far-UVC Air Disinfection.

Annals of the American Thoracic Society·2024
Same author

Treatment Effects of Therapeutic-Dose Heparin in Patients Hospitalized for COVID-19.

JAMA·2023
Same author

"Pulmonary embolism response teams: Changing the paradigm in the care for acute pulmonary embolism": comment.

Journal of thrombosis and haemostasis : JTH·2023
Same author

Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional study.

Journal of thrombosis and haemostasis : JTH·2023
Same journal

Multi target effects of Allium macrostemon against myocardial infarction: an integrated network pharmacology, molecular docking, and experimental study.

Journal of thrombosis and thrombolysis·2026
Same journal

Comparative effectiveness of figure-of-eight suture and manual compression for femoral venous hemostasis after atrial fibrillation ablation: A grade assessed meta-analysis.

Journal of thrombosis and thrombolysis·2026
Same journal

Tissue factor-related biomarkers during combined androgen blockade in patients with prostate cancer: A brief report.

Journal of thrombosis and thrombolysis·2026
Same journal

Opioid use disorder and clinical outcomes following percutaneous coronary intervention for acute coronary syndromes.

Journal of thrombosis and thrombolysis·2026
Same journal

Sex-based differences in clinical outcomes among cardiogenic shock patients treated with mechanical circulatory support.

Journal of thrombosis and thrombolysis·2026
Same journal

IGF-1 axis: The signalling bond in cancer-associated thrombosis and cachexia?

Journal of thrombosis and thrombolysis·2026
See all related articles

New anticoagulants, including synthetic pentasaccharides and direct oral inhibitors, offer novel mechanisms for preventing blood clots. These agents target Factor Xa or thrombin, representing advancements beyond traditional vitamin K antagonists.

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Emergence of novel anticoagulant agents with diverse properties and economic implications.
  • Limitations of existing anticoagulant therapies necessitate development of new options.

Purpose of the Study:

  • To review and discuss new anticoagulant agents, including synthetic pentasaccharides and direct oral anticoagulants.
  • To highlight their mechanisms of action, clinical applications, and potential advantages.

Main Methods:

  • Review of scientific literature and clinical trial data on novel anticoagulant agents.
  • Analysis of mechanisms of action, focusing on inhibition of coagulation factors.
  • Comparison of different anticoagulant classes, including pentasaccharides and direct inhibitors.

Related Experiment Videos

Main Results:

  • Synthetic pentasaccharides (fondaparinux, idraparinux) bind antithrombin to inhibit Factor Xa.
  • Injectable melagatran and oral anticoagulants (ximelagatran, razaxaban) directly inhibit thrombin or Factor Xa.
  • Oral anticoagulants like ximelagatran demonstrate efficacy in clinical trials.

Conclusions:

  • Novel anticoagulants offer alternative therapeutic strategies for thromboembolic disorders.
  • Directly acting oral anticoagulants represent a significant advancement in anticoagulant therapy.
  • Further research is needed to fully elucidate the risks, benefits, and economic impact of these new agents.